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Providing blood units for patients with an antibody to a high-
prevalence antigen or with multiple common antibodies is a 
constant challenge to the blood banks. Finding a compatible donor 
requires extensive screening, which incurs a large amount of 
investment. In this article, we share our experience of organizing 
a rare donor inventory with limited resources, we include the 
strategy used for finding rare donors, and we share the difficulties 
found during the implementation of the approach and the results 
obtained. Immunohematology 2015;31:20–23.
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Rare donor identification began to get attention in 
the 1960s when the American Red Cross and American 
Association of Blood Banks began compiling a rare donor 
database.1 Both institutions realized that ensuring blood 
supply for patients with antibodies to high prevalence antigens 
or with multiple common antibodies was a big challenge.1,2 
Thereafter, rare donor programs were created in some 
countries and, in 1998, a national American program was 
formed (the American Rare Donor Program)1 to manage and 
supply rare blood, which currently provides approximately 
1800 units per year in the United States.1,3 Concomitantly, 
in 1965, the International Society of Blood Transfusion 
(ISBT) established the International Panel of Rare Blood 
Donors gathered by the International Blood Group Reference 
Laboratory in Bristol, U.K. Consequently, since 1984, when 
the ISBT Working Party on Rare Donors was formed, the 
provision of an effective exchange program has been discussed 
worldwide.4,5 In 2004, the ISBT Working Party on Rare 
Donors reported that the International Panel of Rare Blood 
Donors held 4000 rare donors registered from 24 countries.5,6 
Other national rare donor programs were also established—
for example, the French program conducted by the French 
National Reference Laboratory for Blood Groups7 and the 
Israeli program headquartered by the Magen David Adom 
National Blood Services.8 Unfortunately, however, there are 
still some countries without a national program.2
Currently, we are starting discussions in Brazil to establish 
a national panel of rare donors. Implementation steps include 
the screening of large numbers of donors, the education 
of blood center personnel, the development of a computer 
system, recruitment of donors, and maintenance of the rare 
units.2 Since 2011, Colsan, a blood bank in São Paulo, has 
implemented a process to screen for rare blood types, trying 
to set a reliable, useful, and efficient strategy to find rare blood 
donors. Taking into account the limitations we have related 
to financial support and the use of different methods, we 
developed an approach to converge resources and strengthen 
the efforts that aim to find the best combination of tests to 
successfully screen large numbers of donors, reduce costs, 
and increase the chances of encountering rare phenotypes and 
genotypes.
Different serology methods, as well as DNA typing, are 
being used to screen rare donors.2 As serology has some 
limitations attributable to the scarcity of commercial and 
potent antisera to type rare antigens, molecular protocols for 
large-scale genotyping have emerged as a tool to overcome 
these restrictions.9,10
Because the definition of what can be considered as rare 
blood differs between countries, the first step is to establish 
which antigens should be screened. It is very difficult to obtain 
a negative example of a high prevalence antigen when it only 
occurs in less than 1 in 1000 individuals.11 Then, finding donors 
whose red cells are negative for multiple common antigens can 
also be a challenge. Therefore, a donor whose red cells lack 
multiple common antigens is also considered a rare donor.
In a multi-ethnic population such as we find in Brazil, 
the prevalence of the different blood group antigens varies 
significantly, and it is necessary to have a range of rare 
blood types available. According to the prevalence of rare 
blood groups in the Brazilian population, we established an 
approach to search for S–s–, k–, Rhnull, r′r′, r″r″, Di(b–), 
Vel–, Wr(b–), Co(a–), Yt(a–), Js(b–), Kp(b–), Jo(a–), and 
Hy– donors. Additionally, we searched for R2R2 donors with 
a combination of negative clinical antigens. This approach 
includes serologic and molecular screening in repeated donors, 
in D– donors, and in donors with RhCE variants. We herein 
share our approach, the difficulties we experienced during 
implementation, and the results obtained after approximately 
3 years of the program.
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Materials and Methods
Rare Donor Screening Strategy
Screening for rare PhenotyPeS in rePeat DonorS
Repeat donors, including group O donors with at least two 
prior donations, are selected for screening by serology as well 
as by DNA typing.
1. Serologic Screening: We first perform a cross-match 
between the donor’s red blood cells (RBCs) and plasmas 
containing antibodies, such as anti-K, anti-Dia, anti-s, and 
anti-E by gel test in an automated instrument (Wadianna, 
Grifols, Barcelona, Spain). To optimize the searching and 
to reduce costs, we mix plasmas with anti-K and anti-Dia 
and perform the tests on the pool. If the test is positive, K 
and Dia are individually typed. All the positive results are 
confirmed with commercial sera.
  The aim of this serologic strategy is to find donors 
with k–, S–s–, and Di(b–) phenotypes and R2R2 donors 
with an interesting combination of antigen-negative 
results. Figure 1 shows the four scenarios obtained 
with this strategy and the further steps performed with 
serologic and molecular protocols.
2. Molecular Screening: Taking into account the lack 
of commercial antisera to type the majority of high-
prevalence antigens and the limitations of conventional 
polymerase chain reaction (PCR), we developed a 
SNaPshot protocol to identify rare donors, as previously 
described by Latini et al.12
Briefly, SNaPshot is a mini-sequencing assay that permits 
analysis of several single nucleotide polymorphisms (SNPs) 
from numerous donors in a short period of time. The protocol 
we developed identifies alleles of the Diego, Colton, Cartwright, 
KEL, Dombrock, and VEL blood group systems. All samples 
previously typed by serology, such as Di(a+) and/or K+, R1r, 
R1R1, R2R2, or R0r are selected for this molecular analysis.
Screening of rare PhenotyPeS in D-negative DonorS
All D– donors are typed for C, E, and K by hemagglu-
tination in microplates using an automated instrument (Neo, 
Immucor, Birkenfeld, Germany). This approach identifies rare 
Rh phenotypes such as r′r′, r″r″, and Rhnull and also the k– 
phenotype in the samples typed as K+. 
Molecular Screening for rhce variantS
Molecular screening for RhCE variants is performed in 
repeat donors of group O African descendants and in donors 
with altered expression of C, c, E, and e. We also perform 
molecular searching for CE variants in donors with altered 
expression of D because RhD variants have been shown to 
be associated with RhCE variants. In these cases, we select 
samples with weak D expression for immediate spin with 
two monoclonal anti-D reagents (IgM RUM-1 and blend 
D175+D415) on an automated instrument (Neo, Immucor).
Because the most important RhCE variants are those 
silencing the high prevalence antigens, hrS and hrB, our 
strategy includes screening the following alleles: RHCE*ceAR, 
RHCE*ceEK, RHCE*ceAG, RHCE*ceMO, RHCE*ceBI, 
RHCE*ceSM, RHCE*ceCF, and RHCE*ceS (RHCE*ce733G) 
that cause the hrS– and/or hrB– phenotypes. To identify 
these variants, we first use a PCR–restriction fragment–
length polymorphism (PCR-RFLP) for detection of the SNPs 
712A>G, 254C>G, 667G>T and 733C>G. Depending on the 
results obtained, we then use a strategy to identify the variant, 
as shown in Figure 2.
Fig. 1. This figure shows the four scenarios obtained by serologic screening. (A) All K+ RBCs are typed for k to identify k– phenotypes. (B) 
s– and K– RBCs are typed for S and all S–s– samples are genotyped for GYPB to identify U– and U+var phenotypes. (C) All Di(a+) and K– 
samples are typed for RhCE. R1r, R1R1, R0r, and R2R2 RBCs are molecular typed by SNaPshot. (D) All E+ K– RBCs are typed for e, and all 
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We also perform molecular tests to identify RhD variants 
in all samples with RhCE variants, based on previously 
published protocols.13 
Results 
Identified rare donors are included in our rare donor 
registry. Table 1 presents the results obtained in our 3 years of 
experience of building our rare donor inventory. To all donors 
included in this inventory, we send a folder with a simple 
explanation of their rare blood type and instructions regarding 
their next donation. We also ask that they keep their contact 
information updated. 
Additionally, we also phenotype and genotype all the 
clinical relevant antigens and freeze RBC aliquots in liquid 
nitrogen. Phenotype information on rare donors is submitted 
to the database housed in our blood center. The database 
allows the identification of the donors and facilitates searching 
for a requested phenotype. The steps of the process are 
schematically described in Figure 2.
The inventory of donors with 
RhCE variants in the homozygous 
state or in the heterozygous state with 
Ce or cE haplotypes allows for RH 
molecular matching to patients with 
sickle cell disease, preventing Rh 
alloimmunization and delayed hemolytic 
transfusion reactions. Six of our 11 
donors with RhCE variants were related 
to RhD variants; all hrS– linked to weak 
D type 4.2.2 and all hrB– linked to weak 
D type 4.0.
Discussion
The strategy presented herein 
has allowed us to search for rare 
donors and to create a rare donor 
inventory at our institution. After 
the complete implementation of the 
molecular laboratory, the investment 
is approximately $2.00 per sample for 
serologic screening and $13.00 per 
sample for SNaPshot screening for RHCE 
variants. The search for D– donors is part 
of our laboratory routine; the additional 
k typing is the equivalent of $0.70 per 
sample. The development of the SNaPshot method has helped 
increase throughput and reduce costs. Therefore, this strategy 
to find rare donors, based on a focused search, is cost-effective 
Fig. 2. Flowchart used to identify hrS– and hrB– donors. The investigation starts with the 
use of polymerase chain reaction–restriction fragment–length polymorphism to detect the 
single nucleotide polymorphisms 712A>G, 254C>G, 667G>T, and 733C>G. According to 
the results, we perform the analyses indicated in the flowchart to identify the RHCE variants.
Table 1. Rare donor inventory
Screening
Total number of 
donors screened
Phenotypes and predicted 
phenotypes from genotypes n





























*U– and U+var were determined by polymerase chain reaction–allele specific 
and restriction fragment–length polymorphism.14
IMMUNOHEMATOLOGY, Volume 31, Number 1, 2015 23
Screening of rare donors in Brazil
as compared with other strategies using microarrays and may 
help other blood centers to build their rare donor inventory.
The benefit of this investment is documented when an 
alloimmunized patient with a rare phenotype requires a rare 
unit of blood and is successfully transfused with a compatible 
unit. In a period of 3 years, we received 18 requests for rare 
units, and 8 of these were fulfilled using our rare donor 
inventory. Applying this approach, we intend to meet the 
needs of the patients with a rare phenotype in our institution 
and help other blood centers.  Nevertheless, we still have some 
limitations to ensure that blood is made available to specific 
patients. Although we observed a great collaboration of the 
donors when recruited, some of these may be unable to donate 
when required. Freezing blood would be a good option, but 
this procedure is currently a challenge in Brazil, since the 
blood bag and the glycerol solution used for freezing are not 
licensed by our regulatory agency.
Limitations of the Approach
Our strategy for searching for rare donors does not include 
screening for D– –, Ge:-2, and Ko phenotypes, which have 
already been found in the Brazilian population, but our future 
screening activities will focus on the identification of such 
donors. Another unfavorable point of this strategy is the long 
duration of the whole process. In general, when we find a rare 
donor, the RBC unit has already been transfused and we need 
to wait until the next donation to freeze RBC aliquots and to 
perform complete phenotyping.
Conclusion
It is widely accepted that a rare donor program is 
important to ensure a safe transfusion. In our experience, 
we realized that the implementation of a rare donor program 
requires efforts from both technical and administrative areas. 
On the other hand, we show herein that a simple and focused 
strategy can help fulfill the requests for units of rare blood for 
patients with antibodies against high-prevalence antigens or 
patients with multiple antibodies. Exchanges of experience 
and collaboration between different centers, through a 
national program, will allow us to ensure that blood will be 
made available to patients with rare blood phenotypes.
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